Header Logo

Connection

Christopher Goetz to Longitudinal Studies

This is a "connection" page, showing publications Christopher Goetz has written about Longitudinal Studies.
Connection Strength

0.699
  1. Visual plus nonvisual hallucinations in Parkinson's disease: development and evolution over 10 years. Mov Disord. 2011 Oct; 26(12):2196-200.
    View in: PubMed
    Score: 0.071
  2. Racial differences may influence the role of cholecystokinin polymorphisms in Parkinson's disease hallucinations. Mov Disord. 2011 Aug 01; 26(9):1781-2.
    View in: PubMed
    Score: 0.070
  3. Hallucinations and sleep disorders in PD: ten-year prospective longitudinal study. Neurology. 2010 Nov 16; 75(20):1773-9.
    View in: PubMed
    Score: 0.068
  4. Cancer incidence in a trial of an antiapoptotic agent for Parkinson's disease. Mov Disord. 2010 Sep 15; 25(12):1801-8.
    View in: PubMed
    Score: 0.067
  5. Comparison of tic characteristics between children and adults. Mov Disord. 2008 Dec 15; 23(16):2407-11.
    View in: PubMed
    Score: 0.060
  6. Does seasonal variation affect hallucinations in PD? A longitudinal study. Mov Disord. 2006 Jun; 21(6):863-5.
    View in: PubMed
    Score: 0.050
  7. Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson's disease patients. Mov Disord. 2006 Feb; 21(2):267-70.
    View in: PubMed
    Score: 0.049
  8. Hallucinations and sleep disorders in PD: six-year prospective longitudinal study. Neurology. 2005 Jan 11; 64(1):81-6.
    View in: PubMed
    Score: 0.045
  9. Prospective longitudinal assessment of hallucinations in Parkinson's disease. Neurology. 2001 Dec 11; 57(11):2078-82.
    View in: PubMed
    Score: 0.037
  10. Prognostic Modeling of Parkinson's Disease Progression Using Early Longitudinal Patterns of Change. Mov Disord. 2021 12; 36(12):2853-2861.
    View in: PubMed
    Score: 0.036
  11. Differential progression of motor impairment in levodopa-treated Parkinson's disease. Mov Disord. 2000 May; 15(3):479-84.
    View in: PubMed
    Score: 0.033
  12. A practical approach to remote longitudinal follow-up of Parkinson's disease: the FOUND study. Mov Disord. 2014 May; 29(6):743-9.
    View in: PubMed
    Score: 0.021
  13. Movement disorder society unified Parkinson disease rating scale experiences in daily living: longitudinal changes and correlation with other assessments. Mov Disord. 2013 Dec; 28(14):1980-6.
    View in: PubMed
    Score: 0.021
  14. A longitudinal program for biomarker development in Parkinson's disease: a feasibility study. Mov Disord. 2009 Oct 30; 24(14):2081-90.
    View in: PubMed
    Score: 0.016
  15. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol. 2008 Jun; 65(6):716-23.
    View in: PubMed
    Score: 0.014
  16. Progression of Parkinson's disease without levodopa. Neurology. 1987 Apr; 37(4):695-8.
    View in: PubMed
    Score: 0.013
  17. Objective assessments of longitudinal outcome in Gilles de la Tourette's syndrome. Neurology. 2003 Oct 14; 61(7):936-40.
    View in: PubMed
    Score: 0.010
  18. Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology. 2003 Jun 10; 60(11):1756-61.
    View in: PubMed
    Score: 0.010
  19. Metric properties of nurses' ratings of parkinsonian signs with a modified Unified Parkinson's Disease Rating Scale. Neurology. 1997 Dec; 49(6):1580-7.
    View in: PubMed
    Score: 0.007
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.